<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medical Instruments &amp; Supplies</title>
	<atom:link href="http://www.stockbloghub.com/category/medicalinstrumentssupplies/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CFN) CareFusion Buying Rowa for $150 Million</title>
		<link>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859</link>
		<comments>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:57:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78859</guid>
		<description><![CDATA[Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million. Rowa, which has customers in 30 countries, specializes in high-speed robotic medication storage and retrieval systems for retail and hospital pharmacies. The company has deployed more than 3,500 automation systems in retail and hospital pharmacies and added 500 new customers last year. In addition to its stronghold in Germany, Rowa has operations in Italy, the Netherlands, Denmark and Sweden. The company’s installations climbed 9% in 2010 and it expanded product sales into Australia, Canada and other new markets during the year. Rowa&#8217;s automated systems, which are used to store and retrieve packaged pharmaceutical inventories, are geared to cut costs and improve workflow. Its products and technologiesare complementary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Decides to Acquire Medegen for $225 Million</title>
		<link>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028</link>
		<comments>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028#comments</comments>
		<pubDate>Thu, 08 Apr 2010 00:24:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33028</guid>
		<description><![CDATA[CareFusion Corporation (CFN) has decided to acquire Medegen for $225 million in cash. CareFusion expects the acquisition to be neutral to the adjusted earnings per share in the first year of operations and increasingly accretive thereafter. The acquisition is expected to be completed by June 30, 2010. Medegen is a leading innovator in infusion therapy which consists of clinically differentiated needle-less access valves and administration sets that deliver intravenous (IV) medication to patients. We believe Medegen would be a ‘strategic fit’ for CareFusion and it will be able to fully integrate Medegen’s operations. Both CareFusion and Medegen have matching infusion product lines and R&#38;D investments. Furthermore, CareFusion’s products are also backed by clinical evidence and differentiation. CareFusion is a medical technology company formed by the spin-off of the Clinical and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/cfn-carefusion-decides-to-acquire-medegen-for-225-million/33028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655</link>
		<comments>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655#comments</comments>
		<pubDate>Thu, 11 Feb 2010 00:21:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27655</guid>
		<description><![CDATA[CareFusion Corporation (CFN) recently reported second quarter fiscal 2010 earnings per share of 39 cents, marginally beating the Zacks Consensus Estimate of 38 cents, but lower than the year-ago earnings of 50 cents. Total revenues in the second quarter increased 5% year over year to $1.0 billion. Growth was witnessed across all business segments. Critical Care Technologies revenues increased 1% year over year to $682 million as a result of higher demand for the company’s respiratory business. Medical Technologies and Services revenues increased 15% year over year to $337 million. Growth was driven by higher sales from the company’s International Surgical Products and Interventional Specialties businesses. CareFusion reported a contraction in margins in the second quarter. Adjusted gross margin declined 200 basis points (bps) year over year to 46.9%. Adjusted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/cfn-carefusion-corporation-beats-consensus-estimates/27655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Enters Agreement with Masimo</title>
		<link>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535</link>
		<comments>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:12:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20535</guid>
		<description><![CDATA[CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Discussed Long-Term Goals</title>
		<link>http://www.stockbloghub.com/2009/09/18/bax-baxter-international-discussed-long-term-goals/15632</link>
		<comments>http://www.stockbloghub.com/2009/09/18/bax-baxter-international-discussed-long-term-goals/15632#comments</comments>
		<pubDate>Fri, 18 Sep 2009 23:53:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15632</guid>
		<description><![CDATA[Baxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and development (R&#38;D) programs at its recently concluded Investor Conference in Chicago. The long-term (5-year) financial objectives are as follows: Increase sales roughly 7% to 8% per annum, excluding foreign exchange translation effect Grow earnings per share in the range of 11% to 13% per annum Generate annual cash flow of approximately $4 billion by 2014 Baxter also plans to expand its strong existing product portfolio by enhancing R&#38;D investments at a compound annual rate of a minimum 8% to 10% from 7% at the end of fiscal 2008. The company will continue to hunt for business development opportunities through its disciplined acquisition strategy. We are confident that Baxter will be able to deliver on its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/bax-baxter-international-discussed-long-term-goals/15632/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Corporation Inks Software Deal</title>
		<link>http://www.stockbloghub.com/2009/09/18/hae-haemonetics-corporation-inks-software-deal/15664</link>
		<comments>http://www.stockbloghub.com/2009/09/18/hae-haemonetics-corporation-inks-software-deal/15664#comments</comments>
		<pubDate>Fri, 18 Sep 2009 23:36:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corp]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15664</guid>
		<description><![CDATA[Haemonetics Corp. (HAE) yesterday announced that it has entered into a deal with Blood Centers of America Inc. (“BCA&#8221;), a cooperative of community blood centers, which will provide BCA members access to Haemonetics’ blood management software. Specifically, the agreement provides the BCA member’s access to Prelude and Interlude, modules of Haemonetics&#8217; integrated Symphony set of products that are designed to automate blood bank operations. Furthermore, BCA members will also have access to Haemonetics’ eQue automated interview and assessment donor screening system. The eQue automated interview and assessment donor screening system is a donor registration and assessment tool designed to assist blood banks and plasma centers in determining a person’s eligibility to donate blood. We feel that this deal will benefit BCA members in a significant manner and will enhance the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/hae-haemonetics-corporation-inks-software-deal/15664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACL) Alcon Aquires Swiss Company and Expands Pipeline</title>
		<link>http://www.stockbloghub.com/2009/09/18/acl-alcon-aquires-swiss-company-and-expands-pipeline/15568</link>
		<comments>http://www.stockbloghub.com/2009/09/18/acl-alcon-aquires-swiss-company-and-expands-pipeline/15568#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:17:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15568</guid>
		<description><![CDATA[Earlier this week, Alcon Inc. (ACL) signed a definitive agreement for the acquisition of Swiss biotech company ESBATech AG. Alcon will pay $150 million in cash at closing. Besides this, Alcon may pay up to $439 million on the achievement of future research and development milestones. With this acquisition, Alcon will gain access to ESBATech’s proprietary antibody fragment technology, which is used for the development of compounds for the treatment of eye diseases like age-related macular degeneration, diabetic macular edema, glaucoma, dry eye and uveitis. ESBATech has several stable and soluble single-chain antibody fragments in development. ESBATech’s lead antibody fragment, ESBA105, is a recombinant humanized scFv antibody fragment directed against human tumor necrosis factor-alpha (TNF?). ESBA105 is being developed for a number of therapeutic indications and is currently in a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/acl-alcon-aquires-swiss-company-and-expands-pipeline/15568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Top Health Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/09/16/bax-top-health-equity-funds-mutual-fund-commentary/15296</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bax-top-health-equity-funds-mutual-fund-commentary/15296#comments</comments>
		<pubDate>Wed, 16 Sep 2009 17:06:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien]]></category>
		<category><![CDATA[Limited]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15296</guid>
		<description><![CDATA[Today we are featuring top-performing “Health&#8221; equity mutual funds, which primarily invest in equity securities of healthcare and related companies. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds. 3 Robust Samples Fidelity Select Medical Equipment &#38; Systems (FSMEX) was incepted in April 1998. The investment seeks capital appreciation by investing in securities of healthcare companies. The fund may invest in securities of foreign issuers and invest a significant percentage of assets in a single issuer. It is non-diversified. The fund’s top holdings include Baxter International Inc. (BAX), Covidien Ltd. (COV) and Medtronic Inc. (MDT). Evergreen Health Care A (EHABX) seeks long-term capital growth. It primarily invests in equity securities of issuers that derive more than 50% of their sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bax-top-health-equity-funds-mutual-fund-commentary/15296/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Fails to Deliver Swine Flu Vaccine</title>
		<link>http://www.stockbloghub.com/2009/09/16/bax-baxter-international-fails-to-deliver-swine-flu-vaccine/15253</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bax-baxter-international-fails-to-deliver-swine-flu-vaccine/15253#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:31:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15253</guid>
		<description><![CDATA[Baxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government to supply required quantities of swine flu vaccine, Celvapan. The company has supplied only half of the 400,000 doses of Celvapan it had agreed to supply by the end of Aug 2009. Britain’s Department of Health allocated Baxter 30 million of the 90 million doses of a $745 million (?450 million) contract placed in May 2009. The remaining 60 million doses were allocated to GlaxoSmithKline plc (GSK). Baxter has already received contracts from five governments Incorporatedluding the Governments of Ireland and New Zealand, for 80 million doses of swine flu vaccines. The company has decided not to sign any more contracts since it is already running behind schedule. The U.K. government is working with Baxter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bax-baxter-international-fails-to-deliver-swine-flu-vaccine/15253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HAE) Haemonetics Corporation Acquires Engineering and Research Associates Inc</title>
		<link>http://www.stockbloghub.com/2009/09/09/hae-haemonetics-corporation-acquires-engineering-and-research-associates-inc/14711</link>
		<comments>http://www.stockbloghub.com/2009/09/09/hae-haemonetics-corporation-acquires-engineering-and-research-associates-inc/14711#comments</comments>
		<pubDate>Wed, 09 Sep 2009 21:56:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corp]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14711</guid>
		<description><![CDATA[Haemonetics Corporation (HAE) has recently acquired the blood collection and processing business of Engineering and Research Associates Inc., commonly known as SEBRA. The transaction is worth $12.5 million in cash and is expected to be completed in a few months time. The SEBRA acquisition expands the vista of Haemonetics’ product offerings and increases its top-line. Furthermore, it strengthens the company’s position in the whole blood collection market. Haemonetics is developing an automated whole blood collection system and expects to launch it in late fiscal 2011. The SEBRA acquisition is expected to be neutral to Haemonetics’ earnings per share in fiscal 2010 and accretive thereafter. SEBRA markets a suite of products such as radio-frequency tube sealers, whole blood collection devices known as shakers, and mobile collection &#38; ancillary equipment. These products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/hae-haemonetics-corporation-acquires-engineering-and-research-associates-inc/14711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NURO) NeuroMetrix Inc Raises Funds</title>
		<link>http://www.stockbloghub.com/2009/09/09/nuro-neurometrix-inc-raises-funds/14710</link>
		<comments>http://www.stockbloghub.com/2009/09/09/nuro-neurometrix-inc-raises-funds/14710#comments</comments>
		<pubDate>Wed, 09 Sep 2009 21:30:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Neurometrix Inc]]></category>
		<category><![CDATA[NURO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14710</guid>
		<description><![CDATA[NeuroMetrix Inc. (NURO) entered into a private placement transaction with institutional investors for $18.68 million worth of its common stock. Per the agreement, the company will sell 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares of common stock. Each unit, comprising a common stock and a warrant to buy 0.95 share, will carry a purchase price of $2.12. NeuroMetrix expects to close the offer later this week. The warrants will expire five years from their date of issuance. NeuroMetrix designs, develops and sells proprietary medical devices to diagnose neuropathies, which are disturbances of the nervous system. Principally, the company offers physicians an in-office diagnostic system named the NC-stat System. The NC-stat System enables physicians to make rapid and accurate diagnoses of peripheral neuropathies Incorporatedluding carpal tunnel syndrome, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/nuro-neurometrix-inc-raises-funds/14710/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Positive SYNTAX for Boston Scientific Stent</title>
		<link>http://www.stockbloghub.com/2009/09/08/bsx-positive-syntax-for-boston-scientific-stent/14589</link>
		<comments>http://www.stockbloghub.com/2009/09/08/bsx-positive-syntax-for-boston-scientific-stent/14589#comments</comments>
		<pubDate>Tue, 08 Sep 2009 23:52:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14589</guid>
		<description><![CDATA[Boston Scientific Corporation (BSX) recently came out with its two-year SYNTAX clinical data that do not typify any statistically significant difference between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. The PCI was performed using the company’s TAXUS Express Paclitaxel-Eluting Coronary Stent System. The composite safety endpoint consisting of different parameters like all-cause death, stroke, and myocardial infarction (MI) demonstrated no significant difference between PCI and CABG. Results in the SYNTAX study were as follows: The combined rate of all-cause death, stroke and MI was 10.8% for PCI, compared to 9.6% for CABG. On an individual parameter basis, the rate of stroke was 1.4% for PCI, compared to 2.8% for CABG. MI was 5.9% for PCI and 3.3% for CABG. All-cause death was 6.2% for PCI versus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/bsx-positive-syntax-for-boston-scientific-stent/14589/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BCR) C.R. Bard &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/09/04/bcr-c-r-bard-bull-of-the-day/14428</link>
		<comments>http://www.stockbloghub.com/2009/09/04/bcr-c-r-bard-bull-of-the-day/14428#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:39:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14428</guid>
		<description><![CDATA[C.R. Bard (BCR) operates in vascular, urology, oncology and surgical specialty markets. These end-markets should remain insulated from the current economic turmoil. Many of the company&#8217;s products are used in interventional medicine &#8212; life-saving surgical procedures. Future quarters will be met with a headwind from foreign exchange. However, with less than a third of sales outside of the United States, the impact will be less than that for BCR&#8217;s competitors. We retain our Outperform rating on the shares. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/bcr-c-r-bard-bull-of-the-day/14428/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COO) Cooper Companies Misses Estimates by 13%</title>
		<link>http://www.stockbloghub.com/2009/09/04/coo-cooper-companies-misses-estimates-by-13/14465</link>
		<comments>http://www.stockbloghub.com/2009/09/04/coo-cooper-companies-misses-estimates-by-13/14465#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:21:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[The Cooper Companies Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14465</guid>
		<description><![CDATA[The Cooper Companies Inc. (COO) reported fiscal third-quarter results yesterday after market close. The company posted GAAP earnings of $21.9 million or 48 cents per share, compared to $17.9 million or 39 cents per share in the year-ago period. Excluding restructuring charges, pro forma earnings per share came in at 54 cents, which missed the Zacks Consensus Estimate by nearly 13%, or 8 cents. Cooper manufactures and markets specialty healthcare products through its CooperVision and CooperSurgical units. CooperVision makes contact lenses to correct visual defects. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women&#8217;s healthcare market. The company has manufacturing facilities in the U.S., U.K., Australia and Spain. The Pleasanton, CA-based company posted a 2% year-over-year growth in sales to $285.2 million. CooperVision unit’s revenue grew 2% year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/coo-cooper-companies-misses-estimates-by-13/14465/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company Receives $52 Million Government Order</title>
		<link>http://www.stockbloghub.com/2009/09/04/bdx-becton-receives-52-million-government-order/14486</link>
		<comments>http://www.stockbloghub.com/2009/09/04/bdx-becton-receives-52-million-government-order/14486#comments</comments>
		<pubDate>Fri, 04 Sep 2009 22:15:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[Harte-Hanks Inc.]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14486</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) received an order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs for use in national flu pandemic preparedness efforts. The order, worth approximately $52 million, is effective through March 2010. The new contract is part of the company’s effort to protect Americans from the H1N1 influenza virus, commonly known as &#8220;swine flu.&#8221; Becton is also in constant touch with governments and vaccine companies across the globe to meet their needs during the flu season. We think that the new contract will boost Becton’s top-line. This will also add to the company’s contribution to social welfare. Becton, Dickinson and Co. develops, manufactures and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/bdx-becton-receives-52-million-government-order/14486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific Registers Positive Results From MADIT Trial</title>
		<link>http://www.stockbloghub.com/2009/09/02/bsx-boston-scientific-registers-positive-results-from-madit-trial/14265</link>
		<comments>http://www.stockbloghub.com/2009/09/02/bsx-boston-scientific-registers-positive-results-from-madit-trial/14265#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:34:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14265</guid>
		<description><![CDATA[BSX: Positive Results from MADIT Trial Boston Scientific Corporation (BSX) announced positive final results from its landmark MADIT-CRT trial. The MADIT trial was conducted to evaluate the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial, engulfing more than 1,800 asymptomatic or mildly symptomatic patients across 110 centers in 14 countries. It is estimated that roughly 22 million people in the world suffer from some form of heart failure, with more than 5.5 million of them being Americans. Class I or II accounted for approximately 70% of all heart failure patients in the U.S. Patients are classified as Class I-II-III-IV by the New York Heart Association based on the degree of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/bsx-boston-scientific-registers-positive-results-from-madit-trial/14265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific is Ready For MADIT Results</title>
		<link>http://www.stockbloghub.com/2009/08/31/bsx-boston-scientific-is-ready-for-madit-results/13972</link>
		<comments>http://www.stockbloghub.com/2009/08/31/bsx-boston-scientific-is-ready-for-madit-results/13972#comments</comments>
		<pubDate>Mon, 31 Aug 2009 20:43:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Incorporated]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13972</guid>
		<description><![CDATA[Boston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which will be announced on Sept 1. The MADIT trial is evaluating the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial engulfing more than 1,800 asymptomatic or mildly symptomatic patients across 110 centers in 14 countries. Preliminary results from this trial were published on June 23, which indicated that the trial met its primary objectives. Results demonstrated a 29% reduction in death or heart failure in patients implanted with CRT-Ds as compared to ICDs. Positive final results will boost demand for Boston’s cardiac resynchronization therapy defibrillators, which will essentially drive the company’s top-line. Boston Scientific reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/bsx-boston-scientific-is-ready-for-madit-results/13972/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MELA) How to Unearth Explosive Small-Cap HealthCare Stocks</title>
		<link>http://www.stockbloghub.com/2009/08/27/mela-how-to-unearth-explosive-small-cap-healthcare-stocks/13693</link>
		<comments>http://www.stockbloghub.com/2009/08/27/mela-how-to-unearth-explosive-small-cap-healthcare-stocks/13693#comments</comments>
		<pubDate>Fri, 28 Aug 2009 00:24:58 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Electro-optical Sciences Inc]]></category>
		<category><![CDATA[MELA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13693</guid>
		<description><![CDATA[by Marc Lichtenfeld, Advisory Panelist How do I know if I’m doing a good job for my readers and subscribers? Simple. The stock market tells me every single day. I’m not someone who needs a pat on the back to feel good about my work.. However, even I’ll admit it’s nice to have my judgment validated – especially when it comes from a well-respected source like Barron’s. That’s what happened last Saturday when the 88-year publication published a story about the small-cap healthcare stock Electro-Optical Sciences (Nasdaq: MELA). As a result, shares soared 19% on Monday. What’s more, the author, Neil Martin, expects the stock to tack on an additional 50%, as the company’s melanoma detection device is expected to gain FDA approval and become a big hit with physicians ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/mela-how-to-unearth-explosive-small-cap-healthcare-stocks/13693/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KNSY) Kensey Beats Consensus Estimate</title>
		<link>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227</link>
		<comments>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227#comments</comments>
		<pubDate>Mon, 24 Aug 2009 20:39:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[Orthovita Incorporated]]></category>
		<category><![CDATA[Spectranetics Corporation]]></category>
		<category><![CDATA[SPNC]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[VITA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13227</guid>
		<description><![CDATA[Kensey Nash Corp. (KNSY) recently reported strong results for the fourth quarter and full year 2009. Quarterly profit came in at 41 cents per share, compared to the Zacks Consensus Estimate of 38 cents and the year-ago loss of 9 cents per share. Quarterly Results Sales Net sales in the quarter were $20.5 million, down about 7% year over year. In terms of business segments, sales of Biomaterials products fell 8% year over year to $12.3 million. Within this segment, Orthopaedic revenue declined 16% year over year to $7 million on lower sales of sports medicines due to the ongoing economic turbulence. This was partly offset by higher sales of the Vitoss Bioactive Foam products to its customer Orthovita Inc. (VITA). Cardiovascular sales rose 8% year over year to $4.5 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($BAX) Baxter International &#8211; ROE of 35%, soaring past the industry average of 8%$</title>
		<link>http://www.stockbloghub.com/2009/07/23/bax-baxter-international-upped-its-full-year-earnings-guidance/11132</link>
		<comments>http://www.stockbloghub.com/2009/07/23/bax-baxter-international-upped-its-full-year-earnings-guidance/11132#comments</comments>
		<pubDate>Thu, 23 Jul 2009 18:55:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=11132</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the consensus estimate by 2% and surpassing the previous year&#8217;s 85 cents. The company also upped its full-year earnings guidance, and analysts followed suit. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company&#8217;s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors&#8217; offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/23/bax-baxter-international-upped-its-full-year-earnings-guidance/11132/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Medical Devices &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016</link>
		<comments>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016#comments</comments>
		<pubDate>Wed, 15 Jul 2009 01:03:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10016</guid>
		<description><![CDATA[Since the beginning of the global economic crisis, medical device stocks have fared slightly worse than the overall market, losing roughly 400 bps more than the S&#38;P500 (-31%) since September 1, 2008, on a market weighted basis. We continue to recommend that investors focus on companies providing life-sustaining products. We believe these products will remain insulated from the longer-term effects of the current economic crisis because target patients will be unable to forego procedures. The initial slide in the market left many strong companies looking very attractive. In the coming year, investors should allocate funds to companies with high earnings quality profiles. We recommend companies with the following characteristics: Size – (1) Larger companies will find it easier to survive any future liquidity issues and acquire new technologies at cents on the dollar.  ?(2) Size also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MMSI) Merit Medical Systems, Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/07/08/merit-medical-systems-inc-aggressive-growth-zacks-rank-buy/9547</link>
		<comments>http://www.stockbloghub.com/2009/07/08/merit-medical-systems-inc-aggressive-growth-zacks-rank-buy/9547#comments</comments>
		<pubDate>Wed, 08 Jul 2009 22:32:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Merit Medical Systems]]></category>
		<category><![CDATA[MMSI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=9547</guid>
		<description><![CDATA[Merit Medical Systems, Inc. (MMSI) boosted its net income by 28% in its latest earnings report. Company Description Merit Medical Systems, Inc. produces single-use medical products of high quality and superior value primarily for use in diagnosis and treatment of cardiovascular disease. The company&#8217;s products are designed to provide physicians and other health care professionals with devices that enable them to perform interventional and diagnostic procedures. Net Income Up 28% On Apr 28 the Utah-based company announced record sales of $58.4 million, 9% higher than the first quarter last year. Net income came in 28% higher at $5.5 million. The record sales drove earnings per share to 19 cents, up from 15 cents in Q1 of 2008. Analysts were only expecting earnings of 16 cents, making this the first surprise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/08/merit-medical-systems-inc-aggressive-growth-zacks-rank-buy/9547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Inc. &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/06/23/bax-baxter-international-inc-growth-and-income-zacks-rank-buy-2/8770</link>
		<comments>http://www.stockbloghub.com/2009/06/23/bax-baxter-international-inc-growth-and-income-zacks-rank-buy-2/8770#comments</comments>
		<pubDate>Tue, 23 Jun 2009 22:00:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8770</guid>
		<description><![CDATA[Baxter International Inc. (BAX) is seeing upbeat estimates ahead of announcing second-quarter results in early July. Analysts are calling for full-year earnings of $3.77 per share, an upward revision of 2 cents over the past 3 months. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company&#8217;s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors&#8217; offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/23/bax-baxter-international-inc-growth-and-income-zacks-rank-buy-2/8770/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien Limited &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/23/cov-covidien-limited-value-zacks-rank-buy/5955</link>
		<comments>http://www.stockbloghub.com/2009/04/23/cov-covidien-limited-value-zacks-rank-buy/5955#comments</comments>
		<pubDate>Thu, 23 Apr 2009 21:36:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5955</guid>
		<description><![CDATA[Covidien Limited (COV), the medical device manufacturer, has surprised on estimates 7 quarters in a row. Will it do it again on Apr 30? Second quarter estimates have risen by nearly 17% in the last 3 months. COV has a forward P/E of 11.35. Company Description Covidien manufactures medical devices, pharmaceutical products and medical supplies. The company has offices in 59 countries and customers in more than 140 countries. First Quarter Produces Earnings Surprise On Jan 26, Covidien reported first-quarter 2009 results that beat Wall Street estimates by 8.57%. The company reported 76 cents compared to analysts&#8217; estimates of 70 cents per share. During a difficult economic period, sales still rose 6% to $2.5 billion from $2.3 billion in the year ago period. Pharmaceutical products were especially strong in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/23/cov-covidien-limited-value-zacks-rank-buy/5955/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company  &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/23/bdx-becton-dickinson-and-company-growth-and-income-zacks-rank-buy-2/5959</link>
		<comments>http://www.stockbloghub.com/2009/04/23/bdx-becton-dickinson-and-company-growth-and-income-zacks-rank-buy-2/5959#comments</comments>
		<pubDate>Thu, 23 Apr 2009 21:32:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5959</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) keeps seeing bullish forecasts on strong fundamentals as the company prepares to report early next week. Analysts are projecting earnings growth of 10.5% for the fiscal year ending September 2009 followed by growth of 10.5% more in fiscal 2010. Company Description Becton, Dickinson and Company is a medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/23/bdx-becton-dickinson-and-company-growth-and-income-zacks-rank-buy-2/5959/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COO) The Cooper Companies, Inc &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/20/coo-the-cooper-companies-inc-value-zacks-rank-buy/5757</link>
		<comments>http://www.stockbloghub.com/2009/04/20/coo-the-cooper-companies-inc-value-zacks-rank-buy/5757#comments</comments>
		<pubDate>Mon, 20 Apr 2009 20:09:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[The Cooper Companies Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5757</guid>
		<description><![CDATA[Cooper Companies, Inc. (COO) analysts are raising estimates and shares are rising consistently. Company Description The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women&#8217;s healthcare market. CooperVision markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. The company also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. Growth and Value Cooper analysts&#8217; estimates are averaging $2.30 for full year 2009, up from $2.15 60 days ago. Forecasts for next year are averaging $2.57, up from $2.45 over the same time span. These forecasts are calling for just 1.6% growth this year, but 12% in 2010. Rates are relatively cheap, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/20/coo-the-cooper-companies-inc-value-zacks-rank-buy/5757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton Dickinson and Company &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/02/bdx-becton-dickinson-and-company-growth-and-income-zacks-rank-buy/5018</link>
		<comments>http://www.stockbloghub.com/2009/04/02/bdx-becton-dickinson-and-company-growth-and-income-zacks-rank-buy/5018#comments</comments>
		<pubDate>Thu, 02 Apr 2009 19:35:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5018</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) continues to see bullish forecasts from Wall Street. Analysts are projecting earnings growth of 10% for the fiscal year ending September 2009 followed by growth of 10% more in fiscal 2010. Company Description Becton, Dickinson and Company is a medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. A Recent Dividend In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/02/bdx-becton-dickinson-and-company-growth-and-income-zacks-rank-buy/5018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COO) The Cooper Companies, Inc. &#8211; Momentum &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/02/coo-the-cooper-companies-inc-momentum-zacks-rank-buy/5016</link>
		<comments>http://www.stockbloghub.com/2009/04/02/coo-the-cooper-companies-inc-momentum-zacks-rank-buy/5016#comments</comments>
		<pubDate>Thu, 02 Apr 2009 19:26:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[The Cooper Companies Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5016</guid>
		<description><![CDATA[The Cooper Companies, Inc. (COO) continues to perform well in a touch market, with the company&#8217;s recent first-quarter results coming in ahead of expectations. Company Description The Cooper Companies, Inc., through its subsidiaries, develops and manufactures healthcare products both domestically and internationally. The company was founded in 1980 and has a market cap of $1.19 billion. Industry Strength Cooper Cos. operates in the medical products industry, a segment of the market that has held up relatively well during the market declines of the last 12 months. This held true when the company reported strong first-quarter results on Mar 5. First-Quarter Results Sales were up 3% to $251.1 million. Income came in at $23.9 million, a huge jump from $6.9 million last year. This produced earnings of 57 cents per share, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/02/coo-the-cooper-companies-inc-momentum-zacks-rank-buy/5016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COO) Cooper Companies, Inc &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/12/coo-cooper-companies-inc-aggressive-growth-zacks-rank-buy/4264</link>
		<comments>http://www.stockbloghub.com/2009/03/12/coo-cooper-companies-inc-aggressive-growth-zacks-rank-buy/4264#comments</comments>
		<pubDate>Thu, 12 Mar 2009 22:50:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[The Cooper Companies Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4264</guid>
		<description><![CDATA[Cooper Companies, Inc. (COO) just reported solid revenue and earnings growth. Margins are improving and shares are on the rise. Company Description The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women&#8217;s healthcare market. CooperVision markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. The company also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. Third Consecutive Surprise On Mar 5 Cooper announce first-quarter results for fiscal 2009 that included earnings per share of 57 cents per share, 43% above the consensus of 40 cents. Earnings rose 50% from last year&#8217;s mark of 38 cents. Earnings were driven by a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/12/coo-cooper-companies-inc-aggressive-growth-zacks-rank-buy/4264/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KNSY) Kensey Nash Corp. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/02/27/kensey-nash-corp-aggressive-growth-zacks-rank-buy/3758</link>
		<comments>http://www.stockbloghub.com/2009/02/27/kensey-nash-corp-aggressive-growth-zacks-rank-buy/3758#comments</comments>
		<pubDate>Fri, 27 Feb 2009 22:45:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KNSY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=3758</guid>
		<description><![CDATA[Kensey Nash Corp. (KNSY) has once again reported record earnings and should post double-digit growth for the next 2 years. Company Description Kensey Nash Corporation designs, develops, manufactures, and processes proprietary biomaterials products for the orthopedics, cardiology, drug/biologics delivery and wound care markets. The company also is involved with cardiovascular medical technology, specifically, arterial revascularization and puncture closure devices. Kensey intends to leverage its proprietary knowledge and expertise to develop new products and technologies and to explore additional applications for its products. EPS More than Doubles On Jan 28 Kensey announced its second-quarter earnings for fiscal 2009 that included earnings per share of 44 cents. The figure was 110% higher than last year&#8217;s 21 cents, and 10% above analyst estimates of 40 cents. This is the second consecutive quarter the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/27/kensey-nash-corp-aggressive-growth-zacks-rank-buy/3758/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International, Inc.  &#8211; Growth And Income &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/02/27/bax-baxter-international-inc-growth-and-income-zacks-rank-buy/3763</link>
		<comments>http://www.stockbloghub.com/2009/02/27/bax-baxter-international-inc-growth-and-income-zacks-rank-buy/3763#comments</comments>
		<pubDate>Fri, 27 Feb 2009 22:44:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=3763</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently declared a quarterly dividend of 26 cents per share, noting that it is payable on April 1 to shareholders of record as of the close of business on March 10. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company&#8217;s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors&#8217; offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 26 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/27/bax-baxter-international-inc-growth-and-income-zacks-rank-buy/3763/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RMD) ResMed Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/02/23/rmd-resmed-inc-aggressive-growth-zacks-rank-buy/3551</link>
		<comments>http://www.stockbloghub.com/2009/02/23/rmd-resmed-inc-aggressive-growth-zacks-rank-buy/3551#comments</comments>
		<pubDate>Mon, 23 Feb 2009 19:02:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Resmed Inc]]></category>
		<category><![CDATA[RMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=3551</guid>
		<description><![CDATA[ResMed, Inc. (RMD) was originally featured as a Zacks Rank Buy in November and has recently announced excellent quarterly results. Company Description ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors. Earnings Surprise On Feb 5 ResMed announced second-quarter results for fiscal 2009 that included $223 million in revenue, a 10% increase over the same period last year. Excluding foreign exchange losses the gain would have been 16%. Earnings per share came in above expectations at 44 cents. Covering analysts were anticipating the company to post 42 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/23/rmd-resmed-inc-aggressive-growth-zacks-rank-buy/3551/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company &#8211; offers an industry-leading yield of 2%</title>
		<link>http://www.stockbloghub.com/2009/02/22/bdx-becton-dickinson-and-company-offers-an-industry-leading-yield-of-2/3372</link>
		<comments>http://www.stockbloghub.com/2009/02/22/bdx-becton-dickinson-and-company-offers-an-industry-leading-yield-of-2/3372#comments</comments>
		<pubDate>Mon, 23 Feb 2009 00:13:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=3372</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 33 cents per share, which is payable on March 31 to shareholders of record on March 10. The company offers an industry-leading yield of 2%. Company Description Becton, Dickinson and Company is a medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. A Recent Dividend In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/22/bdx-becton-dickinson-and-company-offers-an-industry-leading-yield-of-2/3372/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COO) The Cooper Companies &#8211; actively cutting costs and focusing on gaining market share</title>
		<link>http://www.stockbloghub.com/2009/02/18/the-cooper-companies-actively-cutting-costs-and-focusing-on-gaining-market-share/2755</link>
		<comments>http://www.stockbloghub.com/2009/02/18/the-cooper-companies-actively-cutting-costs-and-focusing-on-gaining-market-share/2755#comments</comments>
		<pubDate>Wed, 18 Feb 2009 16:08:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[The Cooper Companies Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2755</guid>
		<description><![CDATA[The Cooper Companies, Inc. (COO), which manufactures contact lenses, beat fourth quarter estimates by 12.07% as it recorded record revenue in fiscal 2008. The company has surprised on estimates 3 out of the last 4 quarters by an average of 4.38%. COO is trading at 9.3x forward earnings. Company Description The Cooper Companies manufactures specialty healthcare products. The company has two divisions: CooperVision and CooperSurgical. CooperVision manufactures soft contact lenses and specializes in lenses for astigmatism, presbyopia and ocular dryness. The company produces monthly, 2-week and daily disposable contact lenses. CooperSurgical manufactures medical devices, diagnostic products and surgical instruments mainly used by gynecologists and obstetricians. Record Revenue in Fiscal 2008 On Dec 9, The Cooper Companies reported fourth-quarter 2008 earnings which beat Wall Street estimates by 12.07%. Earnings per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/18/the-cooper-companies-actively-cutting-costs-and-focusing-on-gaining-market-share/2755/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International &#8211; ROE of 31% more than doubles the industry average of 12%</title>
		<link>http://www.stockbloghub.com/2009/02/09/baxter-international-roe-of-31-more-than-doubles-the-industry-average-of-12/2612</link>
		<comments>http://www.stockbloghub.com/2009/02/09/baxter-international-roe-of-31-more-than-doubles-the-industry-average-of-12/2612#comments</comments>
		<pubDate>Mon, 09 Feb 2009 22:27:32 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2612</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently reported record results for 2008, surpassing its guidance. The company also sees double-digit earnings growth in 2009. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 26 countries and sells them in more than 100 countries. Quarterly Report Shows Record ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/09/baxter-international-roe-of-31-more-than-doubles-the-industry-average-of-12/2612/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; Earnings per share came in 86% higher than the forecast</title>
		<link>http://www.stockbloghub.com/2009/01/29/thor-thoratec-corporation-earnings-per-share-came-in-86-higher-than-the-forecast/2424</link>
		<comments>http://www.stockbloghub.com/2009/01/29/thor-thoratec-corporation-earnings-per-share-came-in-86-higher-than-the-forecast/2424#comments</comments>
		<pubDate>Thu, 29 Jan 2009 23:48:35 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2424</guid>
		<description><![CDATA[Thoratec Corporation (THOR) is coming off of an excellent quarterly announcement that showed a spike in revenue and another earnings surprise. Shares are also benefiting from a newly formed level of support. Company Description Thoratec Corporation provides cardiac support devices for use by patients with acute or chronic heart failure. Some of the products will pump blood through the heart for prolonged periods of time in the event of cardiac arrest. The company is headquartered in Pleasanton, California, employs more than 1,000 people internationally, and carries a market cap of $1.36 billion. Another Earnings Surprise On Oct 30 Thoratec announced third quarter results including a 44% increase in revenues. Total revenues for the quarter were $80.8 million up from $56.1 million, one year ago. Earnings per share came in at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/29/thor-thoratec-corporation-earnings-per-share-came-in-86-higher-than-the-forecast/2424/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; 27% earnings growth projection</title>
		<link>http://www.stockbloghub.com/2009/01/26/thor-thoratec-corporation-27-earnings-growth-projection/2334</link>
		<comments>http://www.stockbloghub.com/2009/01/26/thor-thoratec-corporation-27-earnings-growth-projection/2334#comments</comments>
		<pubDate>Mon, 26 Jan 2009 19:42:41 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2334</guid>
		<description><![CDATA[Thoratec Corp.&#8217;s (THOR) share price has continued to move higher since originally being featured as a momentum stock in early December. A trend line that has been supporting prices for the last 3 months is now being pressured just above $29. Third-Quarter Results Thoratec&#8217;s recent price strength comes on the heels of the company&#8217;s solid third-quarter results, reported in late October. Revenue was up 44% to $80 million. Earnings came in at 13 cents per share, almost doubling analyst estimates of 7 cents. Analyst Estimates Analyst estimates have continued to tick higher over the last 3 months, with the current-year estimate up 7 cents to 45 cents per share. The next-year estimate is pegged at $57 cent, a 27% earnings growth projection. The Chart This stock has been fairly range ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/26/thor-thoratec-corporation-27-earnings-growth-projection/2334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RMD) Your Individual Retirement Account (IRA): Resolutions for Wealth &amp; Happiness in 2009</title>
		<link>http://www.stockbloghub.com/2009/01/06/rmd-your-individual-retirement-account-ira-resolutions-for-wealth-happiness-in-2009/1917</link>
		<comments>http://www.stockbloghub.com/2009/01/06/rmd-your-individual-retirement-account-ira-resolutions-for-wealth-happiness-in-2009/1917#comments</comments>
		<pubDate>Tue, 06 Jan 2009 18:19:09 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Resmed Inc]]></category>
		<category><![CDATA[RMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1917</guid>
		<description><![CDATA[Your Individual Retirement Account (IRA): Resolutions for Wealth &#38; Happiness in 2009 by David Fessler, Advisory Panelist, Investment U Wednesday, December 31, 2008: Issue #908 Tonight, we look to the New Year and, hopefully, our resolutions for wealth and happiness in 2009. For many, it could be as simple as saving more and contributing to an IRA account. It’s one of the easiest ways to secure a comfortable future. Unless you’ve just arrived from another country, most of you reading this know IRA stands for an Individual Retirement Account. It’s probably a safe bet that many of you have them and make regular contributions to one, or to a similar workplace retirement account. Perhaps you have plans to ultimately use the money to fund your retirement, help out with children ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/06/rmd-your-individual-retirement-account-ira-resolutions-for-wealth-happiness-in-2009/1917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VASC) Vascular Solutions &#8211; impressive financial profile, ROE of 21% against the industry average of just 2%</title>
		<link>http://www.stockbloghub.com/2008/12/30/vasc-vascular-solutions-impressive-financial-profile-with-its-roe-coming-in-at-21-against-the-industry-average-of-just-2/1899</link>
		<comments>http://www.stockbloghub.com/2008/12/30/vasc-vascular-solutions-impressive-financial-profile-with-its-roe-coming-in-at-21-against-the-industry-average-of-just-2/1899#comments</comments>
		<pubDate>Wed, 31 Dec 2008 00:01:39 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[VASC]]></category>
		<category><![CDATA[Vascular Solutions]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1899</guid>
		<description><![CDATA[Vascular Solutions, Inc.&#8217;s (VASC) share price has rebounded after dipping lower in late November. This Zacks #1 rank stock operates in an industry rank #22 out of 217. Estimates Analyst estimates have continued to tick higher, with the current-year estimate edging up to 21 cents per share in the last 30 days. The next-year estimate is pegged at 39 cents, an impressive 81% earnings growth projection. Financial Statistics Vascular Solutions has an impressive financial profile, with its ROE coming in at 21% against the industry average of just 2%. The company also has a solid balance sheet, carrying no debt. The Chart As previously mentioned, shares of VASC have been rallying since bottoming out just above $6 in late November. Sine then, this stock has traded just short of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/30/vasc-vascular-solutions-impressive-financial-profile-with-its-roe-coming-in-at-21-against-the-industry-average-of-just-2/1899/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LMNX) Luminex Corp &#8211; next-year estimate pegged at a whopping 359% earnings growth projection</title>
		<link>http://www.stockbloghub.com/2008/12/18/luminex-corp-next-year-estimate-pegged-at-a-whopping-359-earnings-growth-projection/1780</link>
		<comments>http://www.stockbloghub.com/2008/12/18/luminex-corp-next-year-estimate-pegged-at-a-whopping-359-earnings-growth-projection/1780#comments</comments>
		<pubDate>Thu, 18 Dec 2008 22:33:19 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1780</guid>
		<description><![CDATA[Luminex Corp. (LMNX) is fresh off the heels of a great quarter in which the company swung into profitability from last year. The next-year estimate is extremely bullish and the company&#8217;s share price is rallying. Company Description Luminex Corp develops and manufactures proprietary biological testing technologies and products for the life sciences industry. The company has a market cap of $886 million. Third-Quarter Results Shares of LMNX have been rallying since the company reported strong third-quarter results on Nov 7. Revenue jumped to $29 million from $19.3 million last year. Income increased to $3.2 million from a loss of $1.9 million. This produced earnings of 8 cents per share, far ahead of analyst estimates of 1 cent. Luminex said that its results benefited from partnerships with Genzyme Corp. and Becton, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/18/luminex-corp-next-year-estimate-pegged-at-a-whopping-359-earnings-growth-projection/1780/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMN) Cantel Medical Corporation &#8211; third time in the last three quarters that the company has surprised and beat estimates</title>
		<link>http://www.stockbloghub.com/2008/12/16/cantel-medical-corporation/1717</link>
		<comments>http://www.stockbloghub.com/2008/12/16/cantel-medical-corporation/1717#comments</comments>
		<pubDate>Tue, 16 Dec 2008 17:13:59 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Cantel Medical Corp]]></category>
		<category><![CDATA[CMN]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1717</guid>
		<description><![CDATA[Cantel Medical Corp. (CMN) is rallying after reporting another strong quarter in early December. The current-year estimate has been rising for the last few months as analysts anticipate strong earnings growth from the company. Company Description Cantel Medical Corp. provides infection prevention and control products for the healthcare market primarily in the United States. The company was founded in 1963 and has a market cap of $212 million. Third-Quarter Results Cantel is fresh off the heels of another impressive quarter, reported on Dec, with results that were easily ahead of estimates. Revenue increased 7% from last year to $64,406, 000. Net income spiked up to $3.33 million, up from last year&#8217;s $1.94 million. This produced earnings of 22 cents per share, safely ahead of analyst estimates of 14 cents. Consistent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/16/cantel-medical-corporation/1717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THOR) Thoratec Corporation &#8211; handily beat analyst estimates last quarter</title>
		<link>http://www.stockbloghub.com/2008/12/04/thoratec-corporation-handily-beat-analyst-estimates-last-quarter/1574</link>
		<comments>http://www.stockbloghub.com/2008/12/04/thoratec-corporation-handily-beat-analyst-estimates-last-quarter/1574#comments</comments>
		<pubDate>Thu, 04 Dec 2008 17:35:40 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1574</guid>
		<description><![CDATA[Thoratec Corp. (THOR) recently swung into profitability from last year, reporting strong third-quarter results that were fueled by the release of a product that was approved by regulators for sale in April. Estimates are on the move and so is Thoratec&#8217;s share price. Company Description Thoratec Corporation provides cardiac support devices for use by patients with acute or chronic heart failure. The company is headquartered in Pleasanton, California, employs more than 1,000 people internationally, and carries a market cap of $1.36 billion. Industry Trend The healthcare and medical devices segments of the market have weathered the recent economic volatility better than many of their peers, carrying the benefit of less elastic demand. This dynamic was evident when Thoratec posted strong third-quarter results on Oct 31. Third-Quarter Results Revenue was up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/04/thoratec-corporation-handily-beat-analyst-estimates-last-quarter/1574/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HRC) Hill-Rom Holdings &#8211; beds and furnishings for hospital patient rooms as well as non-invasive therapeutic products for acute and chronic medical conditions</title>
		<link>http://www.stockbloghub.com/2008/11/28/hill-rom-holdings-beds-and-furnishings-for-hospital-patient-rooms-as-well-as-non-invasive-therapeutic-products-for-acute-and-chronic-medical-conditions/1503</link>
		<comments>http://www.stockbloghub.com/2008/11/28/hill-rom-holdings-beds-and-furnishings-for-hospital-patient-rooms-as-well-as-non-invasive-therapeutic-products-for-acute-and-chronic-medical-conditions/1503#comments</comments>
		<pubDate>Fri, 28 Nov 2008 22:35:39 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[HRC]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1503</guid>
		<description><![CDATA[Hill-Rom Holdings Inc. (HRC) reaffirmed 2009 guidance despite the rough economic environment as revenues grew 14.1% in the fourth quarter. HRC surprised on estimates by 7.41% in the fourth quarter. Hill-Rom is trading at 12.8x forward earnings. Company Description Hill-Rom manufactures beds and furnishings for hospital patient rooms as well as non-invasive therapeutic products for acute and chronic medical conditions. Founded in 1929, during the Great Depression, the company was a division of Hillenbrand Industries until March 2008 when Hillenbrand spun off the Batesville Casket Company into a free-standing public company with the name Hillenbrand, Inc. Hillenbrand Industries then renamed itself Hill-Rom Holdings, Inc. Hill-Rom&#8217;s customers include hospitals, long-term care facilities and home care settings world wide. The company has manufacturing and offices in North and South Carolina, Minnesota, Massachusetts ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/11/28/hill-rom-holdings-beds-and-furnishings-for-hospital-patient-rooms-as-well-as-non-invasive-therapeutic-products-for-acute-and-chronic-medical-conditions/1503/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RMD) ResMed Inc &#8211; PEG ration is 1.1, compared to an industry average of 1.7</title>
		<link>http://www.stockbloghub.com/2008/11/26/resmed-inc-peg-ration-is-11-compared-to-an-industry-average-of-17/1486</link>
		<comments>http://www.stockbloghub.com/2008/11/26/resmed-inc-peg-ration-is-11-compared-to-an-industry-average-of-17/1486#comments</comments>
		<pubDate>Wed, 26 Nov 2008 20:06:42 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[RMD]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1486</guid>
		<description><![CDATA[ResMed (RMD) announced record quarterly revenues and income. Shares are enticing as they trade at a discount to the industry averages. Company Description ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. Record-Breaking Income ResMed announced results for the first quarter of fiscal 2009 that included record revenue and income. Revenue rose 17% year-over-year to $218 million. Net income was $28 million, 16% higher than the same quarter in 2007. Earnings per share rose 16% to 36 cents. While the reported earnings were 2 cents below analyst estimates, consensus estimates have been increasing across the board. Estimates on the Rise Since the earnings announcement, the estimate for next year has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/11/26/resmed-inc-peg-ration-is-11-compared-to-an-industry-average-of-17/1486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VASC) Vascular Solutions &#8211; optimism is predicated on Vascular&#8217;s plans to launch 10 new products</title>
		<link>http://www.stockbloghub.com/2008/11/05/vascular-solutions-optimism-is-predicated-on-vasculars-plans-to-launch-10-new-products/1244</link>
		<comments>http://www.stockbloghub.com/2008/11/05/vascular-solutions-optimism-is-predicated-on-vasculars-plans-to-launch-10-new-products/1244#comments</comments>
		<pubDate>Wed, 05 Nov 2008 16:22:25 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[VASC]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1244</guid>
		<description><![CDATA[Vascular Solutions, Inc. (VASC) reported a record quarter last week in which net income almost doubled from the same period last year. The company is scheduled to release a number of new products into its domestic and international markets over the next 6 months that it expects to produce robust earnings growth in 2009. Company Description Vascular Solutions, Inc. is a medical devices company that develops medical supplies for cardiologists and radiologists in the U.S. and internationally. The company was founded in 1996 and has a market cap of $154 million. Third-Quarter Results Vascular Solutions is fresh off the heels of a very solid third quarter, reported on Oct 21. Revenue was up 18% from last year to $15.5 million. Net income totaled $1.72 million, up from $15,000 last year. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/11/05/vascular-solutions-optimism-is-predicated-on-vasculars-plans-to-launch-10-new-products/1244/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company &#8211; return on equity (ROE) of 23%, exceeding the industry average of 17%</title>
		<link>http://www.stockbloghub.com/2008/10/30/becton-dickinson-and-company-return-on-equity-roe-of-23-exceeding-the-industry-average-of-17/1176</link>
		<comments>http://www.stockbloghub.com/2008/10/30/becton-dickinson-and-company-return-on-equity-roe-of-23-exceeding-the-industry-average-of-17/1176#comments</comments>
		<pubDate>Thu, 30 Oct 2008 15:09:09 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1176</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) offers a return on equity of 23%, exceeding the industry average of 17%. The company’s dividend yield of 1.7% is also ahead of the industry average as most of BDX’s peers pay no income. BDX is scheduled to release fiscal fourth quarter results on Nov 05. Company Description Becton, Dickinson and Company is a medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The company serves healthcare institutions, life ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/30/becton-dickinson-and-company-return-on-equity-roe-of-23-exceeding-the-industry-average-of-17/1176/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) &#8211; Covidien &#8211; Sales were up 14% from last year</title>
		<link>http://www.stockbloghub.com/2008/10/07/cov-covidien-sales-were-up-14-from-last-year-5/677</link>
		<comments>http://www.stockbloghub.com/2008/10/07/cov-covidien-sales-were-up-14-from-last-year-5/677#comments</comments>
		<pubDate>Tue, 07 Oct 2008 20:10:18 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=677</guid>
		<description><![CDATA[Covidien Ltd. (COV) has been driving its revenue higher from robust sales in its international markets, which all recorded double-digit sales growth in the most recently reported quarterly results. The next-year estimate is bullish, and the company&#8217;s stock price is in rally mode, hitting a new 52-week and all-time high within the last 3 days. Covidien Ltd. develops and manufactures healthcare products for home and clinical applications worldwide. The company&#8217;s four divisions are Medical Devices, Pharmaceutical Products, Imaging Solutions and Medical Supplies. Covidien was incorporated in 2000, has a market cap of $28 billion and is headquartered in Hamilton, Bermuda. Second-Quarter Results Covidien stepped up and reported solid second-quarter results on Aug 5, driven by strong growth in three of the company&#8217;s four primary business segments. Sales were up 14% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/10/07/cov-covidien-sales-were-up-14-from-last-year-5/677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

